Analysts See $0.96 EPS for Acorda Therapeutics, Inc. (ACOR)

January 13, 2018 - By Migdalia James

 Analysts See $0.96 EPS for Acorda Therapeutics, Inc. (ACOR)
Investors sentiment decreased to 1.22 in 2017 Q3. Its down 0.03, from 1.25 in 2017Q2. It dropped, as 19 investors sold Acorda Therapeutics, Inc. shares while 39 reduced holdings. 22 funds opened positions while 49 raised stakes. 51.31 million shares or 4.56% more from 49.07 million shares in 2017Q2 were reported.
Proshare Advsrs Limited Liability Com invested in 30,161 shares or 0.01% of the stock. Leucadia Corp stated it has 0.03% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Northern Trust Corporation holds 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 1.05M shares. Shanda Asset Mngmt holds 25,957 shares. Bancorporation Of Montreal Can has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Ny State Common Retirement Fund reported 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Manufacturers Life Insurance Co The has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR). First Mercantile Co holds 0.01% or 2,400 shares. Blackrock has invested 0.01% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Aperio Gru Limited Company has 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Pictet Asset Mngmt Limited invested in 123,300 shares. Partner Fund Mngmt Lp has invested 1.88% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Texas Permanent School Fund has invested 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Pinebridge Investments L P owns 0.04% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 67,951 shares. Clearbridge Invs Limited Liability Corporation reported 949,265 shares.

Since July 31, 2017, it had 1 insider purchase, and 4 insider sales for $14.08 million activity. RAUSCHER STEVEN M also sold $215,703 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) on Tuesday, August 1. Randall Lorin sold $216,615 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) on Monday, July 31. $6,350 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) shares were sold by LAWRENCE DAVID. On Tuesday, August 1 Greene Barry E sold $215,697 worth of Acorda Therapeutics, Inc. (NASDAQ:ACOR) or 10,000 shares.

Analysts expect Acorda Therapeutics, Inc. (NASDAQ:ACOR) to report $0.96 EPS on February, 13.They anticipate $1.03 EPS change or 1,471.43 % from last quarter’s $-0.07 EPS. ACOR’s profit would be $44.86M giving it 6.73 P/E if the $0.96 EPS is correct. After having $-0.55 EPS previously, Acorda Therapeutics, Inc.’s analysts see -274.55 % EPS growth. The stock increased 0.98% or $0.25 during the last trading session, reaching $25.85. About 374,748 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 40.68% since January 13, 2017 and is downtrending. It has underperformed by 57.38% the S&P500.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Ratings Coverage

Among 14 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 4 have Buy rating, 2 Sell and 8 Hold. Therefore 29% are positive. Acorda Therapeutics had 38 analyst reports since August 25, 2015 according to SRatingsIntel. Piper Jaffray initiated the shares of ACOR in report on Tuesday, November 28 with “Hold” rating. The rating was upgraded by JP Morgan to “Overweight” on Wednesday, November 30. Goldman Sachs upgraded the stock to “Neutral” rating in Wednesday, February 15 report. The rating was downgraded by Raymond James on Thursday, November 16 to “Underperform”. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Neutral” rating given on Tuesday, August 25 by JP Morgan. On Wednesday, November 8 the stock rating was initiated by Oppenheimer with “Hold”. Cowen & Co maintained the stock with “Buy” rating in Monday, June 5 report. Cowen & Co maintained the shares of ACOR in report on Wednesday, November 15 with “Buy” rating. J.P. Morgan maintained Acorda Therapeutics, Inc. (NASDAQ:ACOR) on Tuesday, June 6 with “Hold” rating. Cantor Fitzgerald maintained the stock with “Hold” rating in Tuesday, October 31 report.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company has market cap of $1.21 billion. The firm markets Ampyra , an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It currently has negative earnings. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

More notable recent Acorda Therapeutics, Inc. (NASDAQ:ACOR) news were published by: Zacks.com which released: “Surging Earnings Estimates Signal Good News for Acorda Therapeutics (ACOR …” on December 18, 2017, also Globenewswire.com with their article: “Kessler Topaz Meltzer & Check, LLP – Important Deadline Reminder for Acorda …” published on January 03, 2018, Wsj.com published: “Acorda Therapeutics Exploring a Potential Sale” on January 05, 2018. More interesting news about Acorda Therapeutics, Inc. (NASDAQ:ACOR) were released by: Prnewswire.com and their article: “Shareholder Class Action Filed Against Acorda Therapeutics, Inc. – ACOR” published on December 14, 2017 as well as Seekingalpha.com‘s news article titled: “Acorda up 12% on potential sale” with publication date: January 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.